Anakinra

阿那白滞素

Report date: 2026/05/22 20:01:29
First In Class

Base Information

Drug NameAnakinra
Drug Alias Name阿那靳雷（Amgen/SOBI）IL-1ra (Amgen/SOBI)阿那白滞素rhIL-1ra (Amgen/SOBI)Anakinrum (Amgen/SOBI) +[10] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterleukin-1 receptor antagonists
TargetsInterleukin-1 receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Polyarticular Juvenile Idiopathic ArthritisPalmoplantar pustulosis +[77] 
Global Approved IndicationsFamilial Mediterranean FeverArthritis, Rheumatoid
Approved Indications in ChinaFamilial Mediterranean Fever
Original Approved Country/TerritoryUnited States
Original Approved Date2001/11/14
Country/TerritoryMainland China(BOAO LECHENG)CanadaUnited States +[21] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesSwedish Orphan Biovitrum AgSobiRadboud University Medical Center +[25] 
Inactive CompaniesUniversity Of StavangerUtah State UniversityUniversity Of California San Francisco +[19] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Polyarticular Juvenile Idiopathic ArthritisPost-Acute COVID-19 Syndrome +[38] 
Inactive IndicationsPalmoplantar pustulosisPustular psoriasisSolid tumours +[39] 

Other Information

ATC CodeL04AC03
Related LinksWikipediaDrugBankKEGG